Although screening using transvaginal ultrasound (TVU) and testing for a protein biomarker called CA-125 alone or in combination can detect early- and late-stage ovarian cancers, it also results in many false-positives, according to a new study. The findings, from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial sponsored and run by the National Cancer Institute, indicate that using these tests may lead to needless surgeries in some patients (Buys et al. Am J Obstet Gynecol. 2005;193:1630-1639).
Hampton T. Ovarian Cancer Tests. JAMA. 2005;294(24):3075. doi:10.1001/jama.294.24.3075-a